XOMA Royalty Completes the Acquisition of Mural Oncology
XOMA Royalty Corporation (Nasdaq: XOMA), a prominent player in the biotech sector, has recently announced the successful completion of its acquisition of Mural Oncology plc (Nasdaq: MURA). This strategic move is poised to enrich XOMA's portfolio, aligning with its mission to improve human health through innovative biotechnology solutions.
Details of the Acquisition
Under this agreement, Mural shareholders received $2.035 in cash for each share, an attractive offer that facilitated a smooth transition. This acquisition was made possible through an Irish High Court sanctioned scheme of arrangement, which is governed by the Companies Act of 2014 in Ireland. x
Shareholder Approval
The acquisition was met with approval from Mural's shareholders at a specialized meeting held pursuant to relevant sections of the Irish Companies Act. The decisive vote took place during the extraordinary general meeting, paving the way for the court's sanction of the scheme.
Trading and Regulatory Updates
As a result of this acquisition, all Mural shares ceased trading on Nasdaq starting December 5, 2025. Following the completion of administrative procedures, Mural will initiate the delisting process from Nasdaq as well as deregistering under the applicable U.S. securities regulations.
Advisors Involved in the Acquisition
XOMA Royalty was advised by several legal and financial advisors throughout this process. Gibson, Dunn & Crutcher LLP and Mason Hayes & Curran LLP served as U.S. and Irish legal advisors, respectively. Davy Corporate Finance UC played a crucial role as the financial advisor to XOMA. On the side of Mural, Lucid Capital Markets, LLC acted as their exclusive financial advisor, supported by Wilmer Cutler Pickering Hale and Dorr LLP and Arthur Cox LLP as their respective legal advisors.
About XOMA Royalty Corporation
XOMA Royalty Corporation continues to be a key influencer in the biotech industry as a royalty aggregator, focusing on acquiring potential future economic returns from both pre-commercial and commercial therapeutic candidates. This innovative approach allows biotech companies to secure vital non-dilutive funding, empowering them to advance their internal drugs or cover corporate costs. The extensive portfolio of XOMA illustrates its commitment to supporting the biotechnology sector and contributing to advancements in human health.
Recent Developments and Future Outlook
With the acquisition of Mural, XOMA is poised to further enhance its offerings and expand its reach within the biotech field. The integration of Mural's innovations aligns seamlessly with XOMA's strategy to drive progress in health solutions and therapeutic advancements. As the market for biologics and cutting-edge therapies grows, XOMA stands to benefit from its strategic investments and partnerships.
Contact Information for Inquiries
XOMA Royalty encourages stakeholders and interested parties to reach out for inquiries. The corporate investor contact is Juliane Snowden, reachable at +1 646-438-9754 or via email at juliane.snowden@xoma.com. Media inquiries can be directed to Kathy Vincent through KV Consulting & Management, with her contact number and email readily available for assistance.
Frequently Asked Questions
What is the recent acquisition by XOMA Royalty?
XOMA Royalty has completed the acquisition of Mural Oncology, enhancing its role in the biotech sector.
How much did Mural shareholders receive in the acquisition?
Mural shareholders received $2.035 in cash for each share they held as part of the acquisition.
What does XOMA Royalty do?
XOMA Royalty is a biotechnology royalty aggregator that acquires potential future economic benefits from therapeutic candidates in exchange for non-dilutive funding.
Who were the advisors involved in the acquisition?
XOMA was advised by Gibson, Dunn & Crutcher LLP and Davy Corporate Finance UC, while Mural was supported by Lucid Capital Markets, LLC.
What will happen to Mural's shares post-acquisition?
Mural's shares ceased trading on Nasdaq, and steps are being taken to delist and deregister these shares under the applicable regulations.
